The FDA has granted a fast track designation to KIN-2787 for use as a potential therapeutic option in patients with BRAF class II or III alteration–positive and/or NRAS mutation–positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
Publications
NICE recommends MSD’s pembrolizumab to treat melanoma
The UK National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab (Keytruda) manufactured by MSD to treat melanoma, the most common form of skin cancer.
FDA Fast Tracks Treatment for Select Stage IIB to IV Malignant Melanoma
KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
New Zealand approves melanoma reimbursement for Opdivo
New Zealand’s Pharmaceutical Management Agency, or PHARMAC, has given a reimbursement approval for Bristol-Myers Squibb’s ($BMY) Opdivo (nivolumab) to treat melanoma, while still in a back-and-forth with Merck ($MRK) on Keytruda (pembrolizumab) for the same indication.